JPWO2022015694A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022015694A5 JPWO2022015694A5 JP2023502572A JP2023502572A JPWO2022015694A5 JP WO2022015694 A5 JPWO2022015694 A5 JP WO2022015694A5 JP 2023502572 A JP2023502572 A JP 2023502572A JP 2023502572 A JP2023502572 A JP 2023502572A JP WO2022015694 A5 JPWO2022015694 A5 JP WO2022015694A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- trp
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 123
- 108090000765 processed proteins & peptides Proteins 0.000 claims 74
- 229920001184 polypeptide Polymers 0.000 claims 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims 71
- 108091008874 T cell receptors Proteins 0.000 claims 23
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 235000018102 proteins Nutrition 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102000016914 ras Proteins Human genes 0.000 claims 10
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims 8
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 8
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 7
- 239000000833 heterodimer Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 238000003259 recombinant expression Methods 0.000 claims 7
- 102100029974 GTPase HRas Human genes 0.000 claims 6
- 102100030708 GTPase KRas Human genes 0.000 claims 6
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 108700020796 Oncogene Proteins 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims 2
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims 2
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims 2
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 102000043600 human HRAS Human genes 0.000 claims 2
- 102000049555 human KRAS Human genes 0.000 claims 2
- 102000047526 human NRAS Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010053491 HLA-DR beta-Chains Proteins 0.000 claims 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 1
- 101150018610 HLA-DRB1 gene Proteins 0.000 claims 1
- 102210026620 HLA-DRB1*03 Human genes 0.000 claims 1
- 101150022563 HLA-DRB3 gene Proteins 0.000 claims 1
- 101150084888 HLA-DRB4 gene Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000009258 tissue cross reactivity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050931P | 2020-07-13 | 2020-07-13 | |
| US63/050,931 | 2020-07-13 | ||
| PCT/US2021/041375 WO2022015694A1 (en) | 2020-07-13 | 2021-07-13 | Hla class ii–restricted drb t cell receptors against ras with g12d mutation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534241A JP2023534241A (ja) | 2023-08-08 |
| JPWO2022015694A5 true JPWO2022015694A5 (enExample) | 2024-07-18 |
Family
ID=77227130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502572A Pending JP2023534241A (ja) | 2020-07-13 | 2021-07-13 | Ｇ１２ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230272038A1 (enExample) |
| EP (1) | EP4178976A1 (enExample) |
| JP (1) | JP2023534241A (enExample) |
| KR (1) | KR20230043881A (enExample) |
| CN (1) | CN116322734A (enExample) |
| AU (1) | AU2021310213A1 (enExample) |
| CA (1) | CA3185241A1 (enExample) |
| WO (1) | WO2022015694A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3209741A1 (en) | 2021-02-26 | 2022-09-01 | Shohei Koide | Compositions and methods comprising antibodies that bind to covalent peptide conjugates |
| CN118852403A (zh) * | 2023-04-26 | 2024-10-29 | 北京鼎成肽源生物技术有限公司 | 靶向kras突变的tcr分子和细胞及其应用 |
| CN120157754A (zh) * | 2023-12-14 | 2025-06-17 | 新景智源生物科技(苏州)有限公司 | Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02006934A (es) * | 2000-01-14 | 2003-01-28 | Corixa Corp | Composiciones y metodos para la terapia y diagnostico de cancer de prostata. |
| CA2497552C (en) | 2002-09-06 | 2014-05-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| AU2017306038B2 (en) * | 2016-08-02 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-KRAS-G12D T cell receptors |
| CN108395479B (zh) * | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| EA202090652A1 (ru) * | 2017-09-20 | 2020-08-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras |
-
2021
- 2021-07-13 WO PCT/US2021/041375 patent/WO2022015694A1/en not_active Ceased
- 2021-07-13 JP JP2023502572A patent/JP2023534241A/ja active Pending
- 2021-07-13 KR KR1020237004523A patent/KR20230043881A/ko active Pending
- 2021-07-13 US US18/015,776 patent/US20230272038A1/en active Pending
- 2021-07-13 CA CA3185241A patent/CA3185241A1/en active Pending
- 2021-07-13 CN CN202180061706.7A patent/CN116322734A/zh active Pending
- 2021-07-13 EP EP21751702.8A patent/EP4178976A1/en active Pending
- 2021-07-13 AU AU2021310213A patent/AU2021310213A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clark et al. | Peptide and nucleotide sequences of rat CD4 (W3/25) antigen: evidence for derivation from a structure with four immunoglobulin-related domains. | |
| GB2609760A (en) | HLA Class I-restricted T cell receptors against RAS with G12D mutation | |
| JP2021505136A5 (enExample) | ||
| RU2752528C2 (ru) | Композиции и библиотеки, содержащие рекомбинантные полинуклеотиды, кодирующие Т-клеточные рецепторы, и способы применения рекомбинантных Т-клеточных рецепторов | |
| JP2020534828A5 (enExample) | ||
| GB2610311A (en) | HLA class I-restricted T cell receptors against RAS with G12V mutation | |
| GB2610069A (en) | HLA class II-restricted T cell receptors against RAS with G12V mutation | |
| Fellah et al. | Conserved structure of amphibian T-cell antigen receptor beta chain. | |
| Briata et al. | Alternative splicing of HLA-DQB transcripts and secretion of HLA-DQ beta-chain proteins: allelic polymorphism in splicing and polyadenylylation sites. | |
| CN120607607A (zh) | 针对含有g12r突变的ras的hla第ii类限制性t细胞受体 | |
| JP2023534241A (ja) | Ｇ１２ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体 | |
| CA2660064A1 (en) | Promiscuous pap cd4 t cell epitopes | |
| JPWO2022015694A5 (enExample) | ||
| Geisler et al. | Structural mutations of C-domains in members of the Ig superfamily. Consequences for the interactions between the T cell antigen receptor and the zeta 2 homodimer. | |
| JPH0198491A (ja) | アルファー遺伝子座中に位置するｔ細胞レセプター遺伝子およびｄｎａ構成物 | |
| Wagner et al. | Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1 | |
| JPWO2020154275A5 (enExample) | ||
| JPWO2022015922A5 (enExample) | ||
| US8658177B2 (en) | Promiscuous HER-2/Neu CD4 T cell epitopes | |
| Miyata et al. | Determination of the molecular nature and cellular localization of Thy-1 in human renal tissue | |
| JP2023535366A (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体 | |
| JPWO2021163477A5 (enExample) | ||
| Rueff-Juy et al. | Effects of neonatal injections of anti-CD3 epsilon monoclonal antibodies on the T cell functions of adult mice. | |
| Hayball et al. | The immune function of MHC class II molecules mutated in the putative superdimer interface | |
| NZ805541A (en) | Hla class i-restricted t cell receptors against mutated ras |